Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide dose reduction for fatigue and cognition in prostate cancer
ACTRN12617000616370Phase 2Not yet recruiting
- Sponsor
- Macquarie University
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Macquarie University. Primary endpoints: Proportion of patients with improvement in cognition and fatigue symptoms and Median total trough level of enzalutamide plus N-desmethyl enzalutamide. Planned start May 2017; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12617000616370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000616370.